Press Release Title Background

Microbial API Market to Grow at a CAGR of 6.98% During 2024 to 2035; Driven by Rising Demand for Microbial-Based Active Pharmaceutical Ingredients and Expanding Pharmaceutical Applications

Report Details:
15 Companies Covered
128 Pages

Microbial API Market Highlights


Microbial API Market is projected to grow from 62.30 USD Billion in 2024 to 131.16 USD Billion by 2035, reflecting a robust growth trajectory.


MRFR recognizes the following companies as the key players in the global microbial API market - Merck & Co., Inc., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Topfond Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Lonza.


The growth of the microbial API market has been mostly attributed to the rising demand for biopharmaceuticals, such as therapeutic proteins and monoclonal antibodies. The industry's growing emphasis on precision medicine is in line with the adaptability of microbially generated APIs in creating complex biomolecules. Furthermore, the pharmaceutical industry's rising emphasis on cost-effectiveness and ecologically friendly procedures has been addressed by the introduction of microbial fermentation technologies, which have shown to be both economically and environmentally sustainable. Pharmaceutical businesses can customize medicines to meet unique therapeutic requirements owing to the high degree of customization provided by microbial APIs, which propels market expansion.


Segment Analysis


The global microbial API market has been segmented into host, type, site, and end user.


On the basis of host, the market is segmented into Mammalian, Bacterial, and Fungal. The mammalian segment was attributed to holding the largest market share in 2023 driven by the industry's continued transition toward novel and biologically derived treatment solutions and the growing demand for biopharmaceuticals, such as recombinant proteins and monoclonal antibodies.


Based on type, the global microbial API market has been segmented into Antibody, Peptide, Protein, Small Molecule, and Vaccine. The antibody segment was expected to hold the largest market share in 2023 because of developments in the field of microbial fermentation technology, which have made it possible to produce these biopharmaceuticals more cheaply and widely. This meets the growing demand for innovative antibody-based therapeutics on a global scale.


Based on site, the global microbial API market has been segmented into In-house and Outsourced. The outsourced segment was expected to hold the largest market share in 2023. The focus of many pharmaceutical businesses has recently shifted to outside providers of manufacturing and R&D services. Because of the constant pressure from regulatory authorities on drug prices, the need for enhanced productivity and efficiency across the value chain, and the surge in demand for customized goods, pharmaceutical enterprises are compelled to rely largely on outsourcing drug development procedures.


Based on end user, the global microbial API market has been segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others. The pharmaceutical companies segment was expected to hold the largest market share in 2023 because of the substantial need for active pharmaceutical ingredients (APIs) produced by microbial fermentation in the pharmaceutical sector. Pharmaceutical firms employ microbial fermentation techniques to produce a broad range of APIs because of the technique's effectiveness, scalability, and cost.


Regional Analysis


The global microbial API market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of  the US and Canada. Europe microbial API market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The microbial API market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World microbial API market comprises the Middle East, Africa, and Latin America.


The North American regional sector maintained the largest market share for microbial API due to the high rates of healthcare spending and highly established healthcare infrastructures in countries like the United States and Canada. The existence of sizable production and research and development (R&D) facilities of top pharmaceutical corporations in the region contributes to the significant domestic usage of microbial API.


Moreover, the Europe market has been persistently growing over the forecast period. Rising healthcare expenses have created new opportunities for the market. The cheap manufacturing cost of microbial APIs, the expanding generics market, the rising prevalence of diseases, including cancer, and increased R&D spending on medication research are some of the key reasons driving market expansion.


Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The rapidly growing pharmaceutical industries in China and India, the influx of foreign investments in production facilities, and the rise of significant domestic drug producers are some of the reasons behind the increase in the consumption of microbial API in Asia Pacific. The growth of this region's market is also being fueled by government initiatives to promote domestic manufacturing.


Furthermore, the rest of the world's microbial API market is divided into the Middle East, Africa, and Latin America. Growing expenditures in the R&D of new antibiotics and a growing emphasis on the creation of microbial-based treatments for chronic illnesses, including diabetes, cancer, and other conditions, are driving the rest of world microbial API market.


Key Findings of the Study



  • The market is expected to achieve a compound annual growth rate (CAGR) of 6.36 percent from 2025 to 2035.

  • By 2035, the market valuation is anticipated to reach 122.7 USD Billion, indicating substantial growth opportunities.

  • in 2024, the market is valued at 62.30 USD Billion, showcasing a strong foundation for future expansion.

  • Growing adoption of microbial APIs due to increasing demand for biopharmaceuticals is a major market driver